12 citations,
January 2016 in “Journal of Clinical and Investigative Dermatology” Low vitamin D levels are common in people with Alopecia Areata.
June 2024 in “JEADV Clinical Practice” Severe alopecia areata patients have a low chance of spontaneous hair regrowth.
April 2022 in “Research Square (Research Square)” The combination of laser and topical steroids is more effective for treating alopecia areata than topical steroids alone.
February 2023 in “Global journal of health sciences and research” Zinc levels are not significantly linked to the presence or severity of alopecia areata.
1 citations,
July 2023 in “Al-Azhar Medical Journal” Higher antigliadin antibodies are linked to more severe alopecia areata, suggesting screening for celiac disease in these patients.
January 2022 in “Al-Azhar Medical Journal” Higher antigliadin antibody levels are linked to alopecia areata severity.
March 2021 in “Actas Dermo-Sifiliográficas” The microbiome may be linked to hair loss and could be a target for new treatments.
June 2017 in “Journal of clinical and investigative dermatology” Red blood cell folate levels are reliable indicators of long-term folate status in alopecia areata patients.
13 citations,
March 2014 in “Journal of Clinical Laboratory Analysis” Higher MIF levels in alopecia areata patients suggest it could be a treatment target and disease predictor.
20 citations,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Researchers created a fast, accurate computer program to measure hair loss in alopecia areata patients.
January 2024 in “JEADV clinical practice” The study helps doctors use patient images to understand and apply SALT scores for treating severe alopecia areata.
Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.
April 2021 in “Research Square (Research Square)” Achieving 80% or more scalp hair regrowth is considered a successful treatment for significant hair loss.
13 citations,
February 2019 in “Journal of the American Academy of Dermatology” The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.
39 citations,
November 2017 in “Journal of The American Academy of Dermatology” The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.
September 2022 in “Journal of Investigative Dermatology” Patient-reported outcomes better reflect the quality of life impact of alopecia areata than traditional severity scores.
2 citations,
February 2014 in “Hair therapy & transplantation” Alopecia Areata is an autoimmune condition causing hair loss, influenced by genetics, environment, and possibly improved by anti-MIF therapy, with many patients experiencing regrowth within a year.
January 2023 in “Przegla̧d dermatologiczny” There are two main types of alopecia areata with different severity, and diagnosis is made through clinical examination and trichoscopy, influencing treatment choices.
238 citations,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
222 citations,
September 2016 in “JCI insight” Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
139 citations,
November 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
130 citations,
February 2018 in “Journal of Investigative Dermatology” Tofacitinib may help treat severe hair loss, but more research is needed.
66 citations,
June 2021 in “Journal of The American Academy of Dermatology” Baricitinib is effective and safe for treating severe alopecia areata.
66 citations,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
49 citations,
May 2018 in “Journal of the American Academy of Dermatology” Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.
49 citations,
March 2017 in “Journal of the American Academy of Dermatology” Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
48 citations,
November 2017 in “Journal of the American Academy of Dermatology” Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
43 citations,
November 2009 in “Archives of dermatology” Alefacept does not effectively treat severe alopecia areata.
42 citations,
November 2018 in “Archives of dermatological research” Apremilast was not effective in treating moderate-to-severe alopecia areata.
38 citations,
June 2015 in “PubMed” Calcipotriol cream can effectively and safely treat mild-to-moderate patchy hair loss.